BioAtla (BCAB) 10-Q 12 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 10, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Entity File Number	001-39787
Entity Registrant Name	BIOATLA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1922320
Entity Address, Address Line One	11085 Torreyana Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	558-0708
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BCAB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,171,560
Entity Central Index Key	0001826892
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Common Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		1,492,059

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 221,199	$ 238,605
Prepaid expenses and other current assets	3,383	2,076
Total current assets	224,582	240,681
Property and equipment, net	4,351	4,102
Other assets	154	154
Total assets	229,087	244,937
Current liabilities:
Accounts payable and accrued expenses	10,331	12,068
Current portion of deferred rent	393	387
Current portion of deferred revenue	19,806	19,806
Total current liabilities	30,530	32,261
Long-term accrued interest	6	5
Deferred rent, less current portion	1,953	2,015
Other debt	682	682
Total liabilities	33,171	34,963
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020 and 2019; 0 shares issued and outstanding at March 31, 2021 and December 31, 2020
Common stock value	3	3
Additional paid-in capital	305,531	300,888
Accumulated deficit	(109,618)	(90,917)
Total stockholders’ equity	195,916	209,974
Total liabilities and stockholders’ equity	229,087	244,937
Class B Units
Stockholders’ equity:
Common stock value	0
Total stockholders’ equity	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	200,000,000	200,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	32,171,560	32,171,560
Common stock, shares outstanding (in shares)	32,171,560	32,171,560
Class B Units
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	15,368,569	15,368,569
Common stock, shares issued (in shares)	1,492,059	1,492,059
Common stock, shares outstanding (in shares)	1,492,059	1,492,059

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Collaboration revenue	$ 0	$ 89
Operating expenses:
Research and development expense	10,423	1,661
General and administrative expense	8,374	463
Total operating expenses	18,797	1,198
Loss from operations	(18,797)	(1,109)
Other income (expense):
Interest income	98	5
Interest expense (includes related party amounts of $0 and $[ ], respectively)	(2)	(547)
Change in fair value of derivative liability	0	47
Total other income (expense)	96	(495)
Consolidated net loss and comprehensive loss	$ (18,701)	$ (1,604)
Net loss per common share, basic and diluted	$ (0.56)
Weighted-average shares of common stock outstanding, basic and diluted	33,663,619

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Interest expense related party	$ 0	$ 59

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Class B Units	Common Stock	Additional Paid-In Capital	Accumulate Deficit
Beginning balance at Dec. 31, 2019	$ (56,011)			$ 2,295	$ (148,354)
Net loss	(1,604)				(1,604)
Ending balance at Mar. 31, 2020	(57,615)			2,295	149,958
Beginning balance at Dec. 31, 2020	209,974	$ 0	$ 3	300,888	(90,917)
Beginning balance, share at Dec. 31, 2020		1,492,059	32,171,560
Stock-based compensation	4,643			4,643
Net loss	(18,701)			0	(18,701)
Ending balance at Mar. 31, 2021	$ 195,916	$ 0	$ 3	$ 305,531	$ (109,618)
Ending balance, share at Mar. 31, 2021		1,492,059	32,171,560

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (18,701,000)	$ (1,604,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	309,000	216,000
Change in fair value of derivative liability	0	(47,000)
Change in fair value and pushdown of profits interest liability	0	(5,703,000)
Stock-based compensation	4,643,000	0
Non-cash interest	0	167,000
Deferred rent	(56,000)	(27,000)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,307,000	(414,000)
Accounts payable and accrued expenses	117,000	2,480,000
Accrued interest	(1,000)	(379,000)
Deferred revenue	0	(89,000)
Net cash used in operating activities	(14,994,000)	(3,814,000)
Cash flows from investing activities
Purchases of property and equipment	(501,000)	(20,000)
Net cash used in investing activities	(501,000)	(20,000)
Cash flows from financing activities
Proceeds from issuance of convertible debt	0	500,000
Payment of initial public offering costs	(1,911,000)	0
Net cash provided by (used in) financing activities	(1,911,000)	500,000
Net decrease in cash and cash equivalents	(17,406,000)	(3,334,000)
Cash and cash equivalents, beginning of period	238,605,000	3,704,000
Cash and cash equivalents, end of period	221,199,000	370,000
Supplemental disclosure of non-cash investing and financing activities
Property and equipment additions included in accounts payable and accrued expenses	$ 74,000	$ 155,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization BioAtla, LLC was formed in Delaware in March 2007 and converted to a Delaware corporation in July 2020 as part of the Corporate Reorganization defined and described below, and was renamed BioAtla, Inc. (the “Company”). The Company has a proprietary platform for creating biologics, including its conditionally active biologics (“CAB” or “CABs”). CABs have been designed to be active only under certain conditions found in diseased tissue, while remaining inactive in normal tissue. The Company is currently in clinical development of its two lead CAB antibody drug conjugates (“CAB ADC”) targeting AXL and ROR2 receptors. Corporate Reorganization and Series D Financing In July 2020, BioAtla, LLC completed a series of transactions (the “Corporate Reorganization”) in connection with the conversion from a limited liability company into a Delaware corporation, the spin-off of Himalaya Therapeutics SEZC, and the completion of a Series D convertible preferred stock financing. The Corporate Reorganization involved the formation of Himalaya Parent LLC as a wholly owned subsidiary of BioAtla, LLC and the formation of BioAtla MergerSub LLC, as a wholly owned subsidiary of Himalaya Parent LLC. Under the Agreement and Plan of Merger (the “Merger Agreement”), BioAtla, LLC was merged into and with BioAtla MergerSub LLC, with BioAtla, LLC surviving, and the members of BioAtla, LLC immediately prior to the effective time of the Merger Agreement received membership interests, on a one-for-one basis, of Himalaya Parent LLC as consideration, and the then-outstanding warrants to purchase equity of BioAtla, LLC were converted into warrants to purchase common shares of common stock of BioAtla, Inc. (see Note 6). The Himalaya Parent LLC operating agreement provided identical equity rights for the then outstanding units of BioAtla, LLC. In addition: (i) the membership interests of BioAtla, LLC held by Himalaya Parent LLC were exchanged for 6,220,050 shares of BioAtla, Inc. common stock, (ii) BioAtla, Inc. issued an aggregate of 59,164,808 shares of Series D convertible preferred stock to Himalaya Parent LLC and Himalaya Parent LLC issued an aggregate of 59,164,808 Class D units to the holders of convertible notes of BioAtla, LLC in connection with the conversion of their convertible notes into Class D units of Himalaya Parent LLC (see Note 4), (iii) BioAtla, LLC distributed to Himalaya Parent LLC its equity interests in Himalaya Therapeutics SEZC, a majority-owned subsidiary which is engaged in the development of a set of antibodies in the field of oncology primarily in Greater China, (iv) Himalaya Parent LLC assumed the profits interest liability of BioAtla, LLC (see Note 7) and (v) BioAtla, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to BioAtla, Inc. Following the Corporate Reorganization, Himalaya Parent LLC owned 59,164,808 shares of BioAtla, Inc. Series D convertible preferred stock and 6,220,050 shares of BioAtla, Inc. common stock. As a result of the subsequent sale of 140,626,711 shares of Series D convertible preferred stock to new investors in July 2020 (see Note 6), BioAtla, Inc. is not controlled by Himalaya Parent LLC (see further discussion in “Principles of consolidation and deconsolidation” below). All pre-Corporate Reorganization operations, employees, property, assets and obligations of BioAtla, LLC (exclusive of the profits interest liability and Himalaya Therapeutics SEZC now held by Himalaya Parent LLC) are held by BioAtla, Inc. Principles of Consolidation and Deconsolidation Prior to the Corporate Reorganization in July 2020, the consolidated financial statements included the accounts of BioAtla, LLC and those of its majority owned subsidiary Himalaya Therapeutics SEZC that had no material operations. Himalaya Therapeutics SEZC also had a wholly owned subsidiary, Himalaya Therapeutics HK Limited that had no material operations. All intercompany balances were eliminated in consolidation. In connection with the Corporate Reorganization, Himalaya Therapeutics SEZC and Himalaya Therapeutics HK Limited were deconsolidated without material impact to the consolidated financial statements. Subsequent to the Corporate Reorganization, Himalaya Parent LLC does not control, is not under common control with, and is not consolidated by BioAtla, Inc. (see Note 9) and BioAtla, Inc. is a single legal entity with no consolidated variable interest entities ("VIEs") or subsidiaries. Liquidity and Going Concern The Company has incurred cumulative operating losses and negative cash flows from operations since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates. As of March 31, 2021, the Company had an accumulated deficit of $ 109.6 million. The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. Management is required to perform a two-step analysis of the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management’s assessment included the preparation of cash flow forecasts resulting in management’s conclusion that there is not substantial doubt about the Company’s ability to continue as a going concern as its current cash and cash equivalents will be sufficient to fund the Company’s operations for a period of at least one year from the issuance date of these unaudited condensed consolidated financial statements. Unaudited Interim Financial Information The unaudited condensed consolidated financial statements as of March 31, 2021, and for the three months ended March 31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”), and with accounting principles generally accepted in the United States (“GAAP”) applicable to interim financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 24, 2021. Use of Estimates The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to revenue recognition, accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Concentrations of Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Income Taxes In March 2021, the American Rescue Plan (H.R. 1319) was signed into law. This legislation extends and enhances a number of current-law tax incentives for businesses, but also expands the definition of a “covered employee” as defined by Section 162(m)(1) of the Internal Revenue Code. The corporate tax provisions included within the bill are not expected to have a material impact on the Company. Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of equity awards, consisting of stock options, restricted stock units (“RSUs”) and employee stock purchase plan rights, over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and employee stock purchase plan rights using the Black-Scholes option pricing model. Prior to the Company’s initial public offering (“IPO”) in December 2020, the fair value of RSUs was based on the estimated fair value of the underlying common stock on the date of grant and, subsequent to the Company’s IPO, the fair value is based on the closing sales price of the Company’s common stock on the date of grant. Equity award forfeitures are recognized as they occur. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss. Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of common stock warrants, RSUs, and common stock options outstanding under the Company’s stock option plan. For the three months ended March 31, 2020, the Company determined that the attribution of pre-Corporate Reorganization net loss based on the post-Corporate Reorganization capital structure would not meaningfully represent the economic rights of the unit holders. As a result, the Company presents net loss per share information only for the period subsequent to the Corporate Reorganization. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalents): March 31, 2021 Common stock warrants 717,674 Common stock options 641,106 Restricted stock units 1,920,037 ESPP shares 1,512 Total 3,280,329 Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use model and requires a lessee to recognize on the balance sheet a right-of-use asset and corresponding lease liability for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for annual periods beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022 and early adoption is permitted. While management is currently assessing the impact this new standard will have, the expected primary impact to its consolidated financial position upon adoption will be the recognition, on a discounted basis, of its minimum commitments under noncancelable operating leases on its consolidated balance sheets resulting in the recording of right of use assets and lease liabilities. The Company’s current minimum commitments under its noncancelable operating leases are disclosed in Note 5.

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	2. Balance Sheet Details Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid research and development $ 1,025 $ 2,004 Prepaid insurance 2,231 — Other prepaid expenses and current assets 127 72 Total $ 3,383 $ 2,076 Property and equipment consist of the following (in thousands): Useful life March 31, December 31, Furniture, fixtures and office equipment 3 - 7 $ 1,870 $ 1,719 Laboratory equipment 5 2,173 1,790 Leasehold improvements 2 - 3 3,687 3,663 7,730 7,172 Less accumulated depreciation and amortization ( 3,379 ) ( 3,070 ) Total $ 4,351 $ 4,102 Accounts payable and accrued expenses consist of the following (in thousands): March 31, December 31, Accounts payable $ 2,505 $ 2,456 Accrued compensation 833 2,804 Accrued research and development 5,921 4,852 Accrued equity issuance costs — 1,143 Other accrued expenses 1,072 813 Total $ 10,331 $ 12,068

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The carrying amounts of the Company’s current financial assets and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of March 31, 2021 and December 31, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. None of the Company’s non-financial assets and liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.

Convertible and Other Debt

Convertible and Other Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible and Other Debt	4. Convertible and Other Debt The Company issued convertible promissory notes between December 2015 and May 2020 totaling $ 21.8 million, of which $ 2.0 million was with related parties. The convertible promissory notes accrued interest at 8 % per annum with maturity dates of five years after issuance . The convertible promissory notes were settled in connection with the Company’s Series D financing in July 2020. As of March 31, 2021, the Company has $ 0.7 million outstanding under a promissory note issued pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act. For the three months ended March 31, 2021 and 2020, the Company recognized interest expense related to its outstanding debt of $ 2,000 and $ 0.5 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Operating Lease In June 2017, as amended in January 2019, the Company entered into a non-cancellable operating lease for its corporate headquarters and laboratory space in San Diego, California. The lease commenced in January 2018, the period the Company gained access to the leased space and began recognizing rent expense. The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. The lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs. Rent expense for the three months ended March 31, 2021 and 2020 was $ 0.4 million and $ 0.4 million, respectively. Expected future minimum payments under the non-cancelable operating lease as of March 31, 2021 are as follows (in thousands): Years ending December 31: Operating 2021 (9 months) $ 1,057 2022 1,555 2023 1,636 2024 1,685 Thereafter 845 $ 6,778 Contingencies From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company is not currently a party to any legal proceedings the outcome of which the Company believes, if determined adversely to the Company, would individually or in the aggregate have a material adverse effect on the Company’s business, operating results or financial condition.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' /Members' Equity (Deficit)	6. Stockholders’/Members' Equity (Deficit) The statement of members' deficit for the three months ended March 31, 2020 is as follows (in thousands, except unit amounts): Class C Preferred Units Class A Units Additional Accumulated Noncontrolling Total Units Amount Units Amount Capital Deficit Interest Deficit Balance at December 31, 2019 23,968,178 $ 89,345 54,600,000 $ 750 $ 2,295 $ ( 148,354 ) $ ( 47 ) $ ( 56,011 ) Net loss — — — — — ( 1,604 ) — ( 1,604 ) Balance at March 31, 2020 23,968,178 $ 89,345 54,600,000 $ 750 $ 2,295 $ ( 149,958 ) $ ( 47 ) $ ( 57,615 ) Initial Public Offering and Related Transactions In December 2020, the Company completed its IPO selling 12,075,000 shares its common stock at $ 18.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $ 198.3 million. In connection with the IPO, all 199,791,519 shares of convertible preferred stock outstanding at the time of the IPO converted into 13,876,510 shares of the Company’s common stock and 1,492,059 shares of the Company’s Class B common stock. 2020 Equity Incentive Plan On October 29, 2020, the Company’s board of directors approved the adoption of the BioAtla, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) and approved certain amendments to the 2020 Plan in December 2020. The Company’s stockholders approved the 2020 Plan, as amended, in December 2020. Under the 2020 Plan, the Company may grant awards of common stock to the Company’s employees, consultants and non-employee directors pursuant to option awards, stock appreciation rights awards, restricted stock awards, restricted stock unit awards, performance stock awards, performance stock unit awards and other stock-based awards. As of March 31, 2021 and December 31, 2020, the total number of common shares reserved for issuance under the 2020 Plan was 6,226,540 and 4,939,678 , respectively. On January 1st of each year, commencing with the first January 1st following the effective date of the 2020 Plan, the shares available for awards under the 2020 Plan shall be increased by a number of shares equal to the lesser of 4% of the total number of shares outstanding on the immediately preceding December 31st and such lesser number of shares determined by the Company’s board of directors. The maximum term of the options granted under the 2020 Plan is no more than ten years. Awards under the 2020 Plan generally vest at 25 % one year from the vesting commencement date and ratably each month thereafter for a period of 36 months , subject to continuous service. There was no stock-based compensation expense reported for the three months ended March 31, 2020 as the 2020 Plan was not yet adopted. Stock-based compensation expense for the three months ended March 31, 2021 has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Research and development $ 954 General and administrative 3,689 Total $ 4,643 Restricted Stock Units The following table summarizes RSU activity under the 2020 Plan for the three months ended March 31, 2021: Number of Weighted - Average Outstanding at December 31, 2020 1,920,037 $ 18.00 Granted — $ — Vested — $ — Outstanding at March 31, 2021 1,920,037 $ 18.00 As of March 31, 2021, total unrecognized stock-based compensation expense for RSUs was $ 34.2 million, which is expected to be recognized over a remaining weighted-average period of approximately 2.7 years. During the three months ended March 31, 2021, the Company modified 138,461 RSU's under the Transition Agreement (See Note 9). Stock Options The following table summarizes stock option activity under the 2020 Plan for the three months ended March 31, 2021 (in thousands, except share and per share data and years): Number of Weighted - Average Weighted -Average Aggregate Balance at December 31, 2020 615,106 $ 18.00 9.95 $ 9,848 Granted 26,000 $ 46.39 Balance at March 31, 2021 641,106 $ 19.15 9.60 $ 20,316 Vested and expected to vest at March 31, 2021 641,106 $ 19.15 9.60 $ 20,316 Exercisable at March 31, 2021 - $ — $ — As of March 31, 2021, total unrecognized stock-based compensation cost for unvested common stock options was $7 .6 million, which is expected to be recognized over a remaining weighted-average period of approximately 3.7 years. The weighted- average grant date fair value of stock options granted, including the impact of modified awards, during the three months ended March 31, 2021 was $ 46.39 per share. During the three months ended March 31, 2021, the Company modified 7,747 stock options under the Transition Agreement (See Note 9). The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, including the impact of modified awards, were as follows: Three Months Expected volatility 76.40 % Risk-free interest rate 0.52 % Expected dividend yield 0.0 % Expected term 4.77 years Expected volatility. As the Company’s common stock does not have a significant trading history, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. Risk-free interest rate. The Company bases the risk-free interest rate assumption on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present plans to pay cash dividends. Expected term. For employees, the expected term represents the period of time that options are expected to be outstanding. Because the Company has minimal historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. For nonemployees, the expected term is generally the contractual term of the option. Employee Stock Purchase Plan In December 2020, the Company’s board of directors and stockholders approved the BioAtla, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP permits participants to purchase common stock through payroll deductions of up to 15 % of their eligible compensation. As of March 31, 2021 and December 31, 2020, a total of 833,993 shares and 464,829 shares, respectively, of common stock were reserved for issuance under the ESPP. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2021 through January 1, 2030 by the least of (i) 1.0 % of the total number of common shares of our common stock outstanding on December 31 of the preceding calendar year (calculated on a fully diluted basis), (ii) 929,658 common shares or (iii) a number determined by the Company’s board of directors that is less than (i) and (ii). In February 2021, employees began to enroll in the ESPP and the Company’s first offering period commenced. Stock-based compensation expense related to the ESPP for the three months ended March 31, 2021 was immaterial. Common Stock Warrants Upon adoption of ASU No. 2018-07 on October 1, 2020, the measurement date of the warrants described below became fixed in accordance with the guidance, and such fair value was nominal since the warrants were deeply out-of-the-money. As of March 31, 2021 all the common stock warrants below are exercisable and expire as follows: Outstanding Exercise Price Expiration Date 566,586 $ 88.25 December 17, 2021 151,088 $ 132.37 March 12, 2022 717,674 Common Stock Reserved for Future Issuance Common stock reserved for future issuance are as follows in common equivalent shares: March 31, December 31, Warrants for the purchase of common stock 717,674 717,674 Common stock options and restricted stock units issued and 2,561,143 2,535,143 Awards available for future issuance under the 2020 Plan 3,665,397 2,404,535 Awards available for future issuance under the ESPP 833,993 464,829 Total common stock reserved for future issuance 7,778,207 6,122,181

Profits Interest Incentive Plan

Profits Interest Incentive Plan	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Profits Interest Incentive Plan	7. Profits Interest Incentive Plan Prior to the Corporate Reorganization in July 2020, the Company maintained a Profits Interest Incentive Plan (the “Plan”) for selected employees, consultants and other service providers. The Class B units generally vested over four years , were subject to continued service requirements, and only provide the participants with benefits (in the form of distributions) if the distributions from BioAtla exceed specified threshold values. Generally, upon termination of services, all unvested Class B units were forfeited to the Company and the Company had the right, but not the obligation, to repurchase the vested Class B units within two years at the termination date fair value. The Class B unit repurchase would be settled in cash, at all times at the option of the Company, and the holder did not have the right to put the Class B units to the Company under any condition. Vested Class B units that are neither repurchased by the Company nor forfeited remained subject to the terms of the Company’s operating agreement. The Class B units were not subject to sale, assignment, transfer, pledge, or allowed to be otherwise encumbered or disposed of without prior written consent of the Company. The Class B units were liability awards pursuant to authoritative guidance, which required the Company to record a liability based on the fair value of the Class B units as of each reporting period. Through the date of the Corporate Reorganization, the fair value of the liability awards was determined based on the Company’s estimated enterprise value, which was allocated based on a hybrid model that, in addition to the option pricing model, considering the Company’s expected IPO. Under the option pricing method, units were valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each unit class. The allocation of equity-based compensation for all Class B units is as follows (in thousands): Three Months Research and development $ ( 2,523 ) General and administrative ( 3,180 ) Total $ ( 5,703 )

Collaboration, License and Opti

Collaboration, License and Option Agreements	3 Months Ended
	Mar. 31, 2021
Collaboration License And Option Agreements [Abstract]
Collaboration, License and Option Agreements	8. Collaboration, License and Option Agreements Global Co-Development and Collaboration Agreement with BeiGene In April 2019, the Company entered into a Global Co-Development and Collaboration agreement (the “BeiGene Collaboration”) with BeiGene, Ltd. and BeiGene Switzerland GmbH (collectively “BeiGene”), a commercial-stage biopharmaceutical company, for the development, manufacturing and commercialization of the Company’s investigational CAB CTLA-4 antibody (BA3071). The Company and BeiGene amended the Global Co-Development and Collaboration agreement in December 2019 and in October 2020 (the “Amended BeiGene Collaboration”). Under the BeiGene Collaboration the Company would co-develop the CAB-CTLA-4 antibody to reach defined early clinical objectives (“POC Milestone”), whereby the Company would perform the development activities (“Development Services”) and BeiGene would reimburse the Company for a portion of the costs incurred by the Company for these Development Services subsequent to the filing of an Investigational New Drug Application (“IND”). Following the POC Milestone, BeiGene would then lead the parties’ joint efforts to develop the product candidate and be responsible for global regulatory filings and commercialization. Subject to the terms of the agreement, BeiGene will hold a co-exclusive license with the Company to develop and manufacture the product candidate globally and an exclusive license to commercialize the product candidate globally. BeiGene will be responsible for all costs of development, manufacturing and commercialization in China, parts of the Middle East and Asia (excluding Japan), Australia and New Zealand (the “BeiGene Territory”), and the parties would share development and manufacturing costs and commercial profits and losses upon specified terms in the rest of the world that are not part of the BeiGene Territory (the “ROW”). Subject to earlier termination, the BeiGene Collaboration shall remain in effect, on a country-by-country basis until the earlier of ten years following commercial sale or upon such time that the parties cease pursuing commercialization. Unless terminated early, at the expiration date BeiGene retains all licensing rights in the applicable territories. BeiGene may terminate the BeiGene Collaboration at any time after the one-year anniversary of the agreement subject to 90 days written notice, or any time subject to 45 days’ notice if it is determined that the proof of concept milestone or technological or scientific feasibility will not be achieved. The BeiGene Collaboration also contains customary provisions for termination by either party, including the event of breach of the BeiGene Collaboration, subject to cure. In 2019, BeiGene paid the Company an upfront non-refundable payment of $ 20.0 million and paid the Company $ 5.0 million for the reimbursement of manufacturing costs. Under the BeiGene Collaboration, the Company was eligible to receive variable consideration for subsequent development and regulatory milestones globally and commercial milestones in the BeiGene Territory and tiered royalties ranging from the mid-single digits to the mid-double digits based on net sales in the BeiGene Territory. The Company concluded that the BeiGene Collaboration is a contract with a customer and applied relevant guidance from Topic 606 through reaching the POC milestone as the licenses to intellectual property granted to BeiGene and the obligation to perform research and development services are outputs of the Company’s ongoing activities. The Company identified material promises in the BeiGene Collaboration through POC milestone, consisting of the licenses described above and the Development Services. It was determined that the licenses are not distinct from the development services resulting in a single performance obligation. In accordance with Topic 606, the Company determined the transaction price of the agreement is limited to the $ 25.0 million received, and excluded the variable consideration of expense reimbursements, milestone payments and royalties as they are fully constrained. The expense reimbursements were included in the transaction price in the reporting period the Company concluded it was probable that inclusion of such amounts in the transaction price would not result in a significant reversal in revenue recognized. As part of the Company’s evaluation of the milestone constraints, the Company determined the achievement of such milestones are contingent upon success in future developments, regulatory approvals and commercial activities which are not within its control and are uncertain at this stage. Variable consideration related to royalties will be recognized when the related sales occur. Under the terms of the Amended BeiGene Collaboration, BeiGene is generally responsible for developing BA3071 and is responsible for global regulatory filings and commercialization. Subject to the terms of the Amended BeiGene Collaboration, BeiGene holds an exclusive license with the Company to develop and manufacture the BA3071 candidate globally, and BeiGene is responsible for all costs of development, manufacturing and commercialization globally. The Amended BeiGene Collaboration provides that the Company is eligible to receive tiered royalties, ranging from the high-single digits to the low twenties, on sales worldwide, up to $ 225.5 million in subsequent development and regulatory milestone payments globally and commercial milestones in the BeiGene territory (reduced from $ 249 million under the BeiGene Collaboration), and a $ 5.0 million milestone payment upon the completion of the Company’s amended performance obligations, including the transfer of the master cell bank for BA3071 and other know-how. Under the Amended BeiGene Collaboration, the Company’s amended performance obligation is satisfied at a point in time determined to be when BeiGene has received the know-how and master cell bank for BA3071. Until then BeiGene cannot benefit from the ability to further develop and manufacture the BA3071 candidate. Under the original collaboration agreement, the Company recognized revenue over time using an input method based on actual costs incurred compared to estimated total costs expected to be incurred to fulfill its performance obligation to perform development services. For the three months ended March 31, 2021 and 2020, the Company recognized revenue of $ 0 and $ 0.1 million, respectively, related to the BeiGene collaboration. As of March 31, 2021 and December 31, 2020, the Company had $ 19.8 million of related deferred revenue which was classified as current. The deferred revenue is expected to be earned upon transfer of the know-how and master cell bank within the next twelve months.

Related party transactions

Related party transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related party transactions	9. Related party transactions Biotech Investment Group, LLC Prior to the Corporate Reorganization, Biotech Investment Group, LLC (“BIG”), was a principal owner, related party of the Company and affiliated with Biotech Investment Group II LLC (“BIG II”). Subsequent to the Corporate Reorganization, BIG is no longer a principal owner and, as a result, neither BIG nor its affiliates are related parties of the Company. Biotech Investment Group II LLC For the three months ended March 31, 2020, the Company recognized interest expense (including amortization of debt discounts) of $ 20,000 related to an outstanding convertible promissory note payable to BIG II. The convertible promissory note payable to BIG II was settled in connection with the Corporate Reorganization in July 2020 . Dr. Jay Short and Carolyn Anderson Short Convertible Promissory Notes For the three months ended March 31, 2020, the Company recognized interest expense (including amortization of debt discounts) of $ 39,000 related to outstanding convertible promissory notes payable to Dr. Jay Short and Carolyn Anderson Short. The convertible promissory notes payable to Dr. Jay Short and Carolyn Anderson Short were settled in connection with the Corporate Reorganization in July 2020 . Transition Agreement On March 18, 2021, the Company and Carolyn Anderson Short, its co-founder and Chief of Intellectual Property & Strategy, mutually agreed that Ms. Short would depart the Company on May 31, 2021 following an agreed upon transition period. The Transition Agreement provides for the following severance benefits in exchange for a release of claims by Ms. Short: (i) a lump sum payment equal to eighteen (18) months of Ms. Short’s current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the separation date, and (iii) accelerated full vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units. The modification of these equity awards resulted in an incremental fair value of $ 7.0 million which will be recognized on a straight-line basis over the transition service period. For the three months ended March 31, 2021, the Company recognized $ 0.2 million related to the lump sum salary payment and target bonus, and a $ 1.0 million non-cash charge related to the modified equity awards.

401(k) Plan

401(k) Plan	3 Months Ended
	Mar. 31, 2021
Compensation And Retirement Disclosure [Abstract]
401(k) Plan	10. 401(k) Plan The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. As of March 31, 2021 and December 31, 2020, the Company had no t made any matching contributions.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Organization	Organization BioAtla, LLC was formed in Delaware in March 2007 and converted to a Delaware corporation in July 2020 as part of the Corporate Reorganization defined and described below, and was renamed BioAtla, Inc. (the “Company”). The Company has a proprietary platform for creating biologics, including its conditionally active biologics (“CAB” or “CABs”). CABs have been designed to be active only under certain conditions found in diseased tissue, while remaining inactive in normal tissue. The Company is currently in clinical development of its two lead CAB antibody drug conjugates (“CAB ADC”) targeting AXL and ROR2 receptors.
Corporate Reorganization and Series D Financing	Corporate Reorganization and Series D Financing In July 2020, BioAtla, LLC completed a series of transactions (the “Corporate Reorganization”) in connection with the conversion from a limited liability company into a Delaware corporation, the spin-off of Himalaya Therapeutics SEZC, and the completion of a Series D convertible preferred stock financing. The Corporate Reorganization involved the formation of Himalaya Parent LLC as a wholly owned subsidiary of BioAtla, LLC and the formation of BioAtla MergerSub LLC, as a wholly owned subsidiary of Himalaya Parent LLC. Under the Agreement and Plan of Merger (the “Merger Agreement”), BioAtla, LLC was merged into and with BioAtla MergerSub LLC, with BioAtla, LLC surviving, and the members of BioAtla, LLC immediately prior to the effective time of the Merger Agreement received membership interests, on a one-for-one basis, of Himalaya Parent LLC as consideration, and the then-outstanding warrants to purchase equity of BioAtla, LLC were converted into warrants to purchase common shares of common stock of BioAtla, Inc. (see Note 6). The Himalaya Parent LLC operating agreement provided identical equity rights for the then outstanding units of BioAtla, LLC. In addition: (i) the membership interests of BioAtla, LLC held by Himalaya Parent LLC were exchanged for 6,220,050 shares of BioAtla, Inc. common stock, (ii) BioAtla, Inc. issued an aggregate of 59,164,808 shares of Series D convertible preferred stock to Himalaya Parent LLC and Himalaya Parent LLC issued an aggregate of 59,164,808 Class D units to the holders of convertible notes of BioAtla, LLC in connection with the conversion of their convertible notes into Class D units of Himalaya Parent LLC (see Note 4), (iii) BioAtla, LLC distributed to Himalaya Parent LLC its equity interests in Himalaya Therapeutics SEZC, a majority-owned subsidiary which is engaged in the development of a set of antibodies in the field of oncology primarily in Greater China, (iv) Himalaya Parent LLC assumed the profits interest liability of BioAtla, LLC (see Note 7) and (v) BioAtla, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to BioAtla, Inc. Following the Corporate Reorganization, Himalaya Parent LLC owned 59,164,808 shares of BioAtla, Inc. Series D convertible preferred stock and 6,220,050 shares of BioAtla, Inc. common stock. As a result of the subsequent sale of 140,626,711 shares of Series D convertible preferred stock to new investors in July 2020 (see Note 6), BioAtla, Inc. is not controlled by Himalaya Parent LLC (see further discussion in “Principles of consolidation and deconsolidation” below). All pre-Corporate Reorganization operations, employees, property, assets and obligations of BioAtla, LLC (exclusive of the profits interest liability and Himalaya Therapeutics SEZC now held by Himalaya Parent LLC) are held by BioAtla, Inc.
Principles of Consolidation and Deconsolidation	Principles of Consolidation and Deconsolidation Prior to the Corporate Reorganization in July 2020, the consolidated financial statements included the accounts of BioAtla, LLC and those of its majority owned subsidiary Himalaya Therapeutics SEZC that had no material operations. Himalaya Therapeutics SEZC also had a wholly owned subsidiary, Himalaya Therapeutics HK Limited that had no material operations. All intercompany balances were eliminated in consolidation. In connection with the Corporate Reorganization, Himalaya Therapeutics SEZC and Himalaya Therapeutics HK Limited were deconsolidated without material impact to the consolidated financial statements. Subsequent to the Corporate Reorganization, Himalaya Parent LLC does not control, is not under common control with, and is not consolidated by BioAtla, Inc. (see Note 9) and BioAtla, Inc. is a single legal entity with no consolidated variable interest entities ("VIEs") or subsidiaries.
Liquidity and Going Concern	Liquidity and Going Concern The Company has incurred cumulative operating losses and negative cash flows from operations since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates. As of March 31, 2021, the Company had an accumulated deficit of $ 109.6 million. The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. Management is required to perform a two-step analysis of the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management’s assessment included the preparation of cash flow forecasts resulting in management’s conclusion that there is not substantial doubt about the Company’s ability to continue as a going concern as its current cash and cash equivalents will be sufficient to fund the Company’s operations for a period of at least one year from the issuance date of these unaudited condensed consolidated financial statements.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited condensed consolidated financial statements as of March 31, 2021, and for the three months ended March 31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”), and with accounting principles generally accepted in the United States (“GAAP”) applicable to interim financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 24, 2021.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to revenue recognition, accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Income Taxes	Income Taxes In March 2021, the American Rescue Plan (H.R. 1319) was signed into law. This legislation extends and enhances a number of current-law tax incentives for businesses, but also expands the definition of a “covered employee” as defined by Section 162(m)(1) of the Internal Revenue Code. The corporate tax provisions included within the bill are not expected to have a material impact on the Company.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of equity awards, consisting of stock options, restricted stock units (“RSUs”) and employee stock purchase plan rights, over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and employee stock purchase plan rights using the Black-Scholes option pricing model. Prior to the Company’s initial public offering (“IPO”) in December 2020, the fair value of RSUs was based on the estimated fair value of the underlying common stock on the date of grant and, subsequent to the Company’s IPO, the fair value is based on the closing sales price of the Company’s common stock on the date of grant. Equity award forfeitures are recognized as they occur.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of common stock warrants, RSUs, and common stock options outstanding under the Company’s stock option plan. For the three months ended March 31, 2020, the Company determined that the attribution of pre-Corporate Reorganization net loss based on the post-Corporate Reorganization capital structure would not meaningfully represent the economic rights of the unit holders. As a result, the Company presents net loss per share information only for the period subsequent to the Corporate Reorganization. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalents): March 31, 2021 Common stock warrants 717,674 Common stock options 641,106 Restricted stock units 1,920,037 ESPP shares 1,512 Total 3,280,329
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use model and requires a lessee to recognize on the balance sheet a right-of-use asset and corresponding lease liability for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for annual periods beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022 and early adoption is permitted. While management is currently assessing the impact this new standard will have, the expected primary impact to its consolidated financial position upon adoption will be the recognition, on a discounted basis, of its minimum commitments under noncancelable operating leases on its consolidated balance sheets resulting in the recording of right of use assets and lease liabilities. The Company’s current minimum commitments under its noncancelable operating leases are disclosed in Note 5.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalents): March 31, 2021 Common stock warrants 717,674 Common stock options 641,106 Restricted stock units 1,920,037 ESPP shares 1,512 Total 3,280,329

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule Of Prepaid Expenses Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid research and development $ 1,025 $ 2,004 Prepaid insurance 2,231 — Other prepaid expenses and current assets 127 72 Total $ 3,383 $ 2,076
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): Useful life March 31, December 31, Furniture, fixtures and office equipment 3 - 7 $ 1,870 $ 1,719 Laboratory equipment 5 2,173 1,790 Leasehold improvements 2 - 3 3,687 3,663 7,730 7,172 Less accumulated depreciation and amortization ( 3,379 ) ( 3,070 ) Total $ 4,351 $ 4,102
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following (in thousands): March 31, December 31, Accounts payable $ 2,505 $ 2,456 Accrued compensation 833 2,804 Accrued research and development 5,921 4,852 Accrued equity issuance costs — 1,143 Other accrued expenses 1,072 813 Total $ 10,331 $ 12,068

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Expected Future Minimum Payments Under The Non Cancelable Operating Lease	Expected future minimum payments under the non-cancelable operating lease as of March 31, 2021 are as follows (in thousands): Years ending December 31: Operating 2021 (9 months) $ 1,057 2022 1,555 2023 1,636 2024 1,685 Thereafter 845 $ 6,778

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of members' deficit	The statement of members' deficit for the three months ended March 31, 2020 is as follows (in thousands, except unit amounts): Class C Preferred Units Class A Units Additional Accumulated Noncontrolling Total Units Amount Units Amount Capital Deficit Interest Deficit Balance at December 31, 2019 23,968,178 $ 89,345 54,600,000 $ 750 $ 2,295 $ ( 148,354 ) $ ( 47 ) $ ( 56,011 ) Net loss — — — — — ( 1,604 ) — ( 1,604 ) Balance at March 31, 2020 23,968,178 $ 89,345 54,600,000 $ 750 $ 2,295 $ ( 149,958 ) $ ( 47 ) $ ( 57,615 )
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense for the three months ended March 31, 2021 has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Research and development $ 954 General and administrative 3,689 Total $ 4,643
Summary of Restricted Stock Units	The following table summarizes RSU activity under the 2020 Plan for the three months ended March 31, 2021: Number of Weighted - Average Outstanding at December 31, 2020 1,920,037 $ 18.00 Granted — $ — Vested — $ — Outstanding at March 31, 2021 1,920,037 $ 18.00
Summary of Stock Option Activity	The following table summarizes stock option activity under the 2020 Plan for the three months ended March 31, 2021 (in thousands, except share and per share data and years): Number of Weighted - Average Weighted -Average Aggregate Balance at December 31, 2020 615,106 $ 18.00 9.95 $ 9,848 Granted 26,000 $ 46.39 Balance at March 31, 2021 641,106 $ 19.15 9.60 $ 20,316 Vested and expected to vest at March 31, 2021 641,106 $ 19.15 9.60 $ 20,316 Exercisable at March 31, 2021 - $ — $ —
Summary of Assumptions Used in Black-Scholes Model	The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, including the impact of modified awards, were as follows: Three Months Expected volatility 76.40 % Risk-free interest rate 0.52 % Expected dividend yield 0.0 % Expected term 4.77 years
Schedule of Common Stock Warrants	As of March 31, 2021 all the common stock warrants below are exercisable and expire as follows: Outstanding Exercise Price Expiration Date 566,586 $ 88.25 December 17, 2021 151,088 $ 132.37 March 12, 2022 717,674
Schedule of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance are as follows in common equivalent shares: March 31, December 31, Warrants for the purchase of common stock 717,674 717,674 Common stock options and restricted stock units issued and 2,561,143 2,535,143 Awards available for future issuance under the 2020 Plan 3,665,397 2,404,535 Awards available for future issuance under the ESPP 833,993 464,829 Total common stock reserved for future issuance 7,778,207 6,122,181

Profits Interest Incentive Pl_2

Profits Interest Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Allocation of equity-based Compensation for all class B units	The allocation of equity-based compensation for all Class B units is as follows (in thousands): Three Months Research and development $ ( 2,523 ) General and administrative ( 3,180 ) Total $ ( 5,703 )

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Organization And Summary Of Significant Accounting Policies [Line Items]
Entity incorporation state country code		DE
Company formation date		2007-03
Entity incorporation, date of incorporation		Jul. 13, 2020
Common stock, shares issued (in shares)	6,220,050	32,171,560	32,171,560
Preferred stock, shares issued (in shares)		0	0
Accumulated deficit		$ 109,618	$ 90,917
Series D Convertible Preferred Stock
Organization And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued (in shares)	59,164,808
Preferred stock, shares issued (in shares)	59,164,808
Subsequent sale of convertible preferred stock to new investors, Shares	140,626,711
Common Stock
Organization And Summary Of Significant Accounting Policies [Line Items]
Preferred stock, shares issued (in shares)	6,220,050

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)	3 Months Ended
	Mar. 31, 2021shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	3,280,329
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	717,674
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	641,106
Restricted Stock Units and Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	1,920,037
ESPP Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	1,512

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule Of Prepaid Expenses Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Prepaid research and development	$ 1,025	$ 2,004
Prepaid insurance	2,231	0
Other prepaid expenses and current assets	127	72
Total	$ 3,383	$ 2,076

Balance Sheet Details - Sched_2

Balance Sheet Details - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 7,730	$ 7,172
Less accumulated depreciation and amortization	(3,379)	(3,070)
Total	4,351	4,102
Furniture Fixtures And Office Equipment
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,870	1,719
Furniture Fixtures And Office Equipment | Minimum
Property Plant And Equipment [Line Items]
Property Plant and Equipment Useful Life	3 years
Furniture Fixtures And Office Equipment | Maximum
Property Plant And Equipment [Line Items]
Property Plant and Equipment Useful Life	7 years
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property Plant and Equipment Useful Life	5 years
Property, Plant and Equipment, Gross	$ 2,173	1,790
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,687	$ 3,663
Leasehold Improvements | Minimum
Property Plant And Equipment [Line Items]
Property Plant and Equipment Useful Life	2 years
Leasehold Improvements | Maximum
Property Plant And Equipment [Line Items]
Property Plant and Equipment Useful Life	3 years

Balance Sheet Details - Sched_3

Balance Sheet Details - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Accounts payable	$ 2,505	$ 2,456
Accrued compensation	833	2,804
Accrued research and development	5,921	4,852
Accrued equity issuance costs	0	1,143
Other accrued expenses	1,072	813
Total	$ 10,331	$ 12,068

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Assets measured at fair value	$ 0	$ 0

Convertible and Other Debt - Ad

Convertible and Other Debt - Additional Information (Details) - USD ($)	3 Months Ended		54 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	May 31, 2020
Debt Instrument [Line Items]
Debt description	The Company issued convertible promissory notes between December 2015 and May 2020 totaling $21.8 million, of which $2.0 million was with related parties. The convertible promissory notes accrued interest at 8% per annum with maturity dates of five years after issuance. The convertible promissory notes were settled in connection with the Company’s Series D financing in July 2020.
Interest Expense	$ 2,000	$ 547,000
Debt Instrument Outstanding Principal Amount	$ 700,000
Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 21,800,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Related Party Transaction, Amounts of Transaction			$ 2,000,000
Debt Instrument, Maturity Date, Description	five years after issuance
Outstanding Debt [Member]
Debt Instrument [Line Items]
Interest Expense	$ 2,000	$ 500,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2021	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Option to extend the term of the lease	The lease commenced in January 2018, the period the Company gained access to the leased space and began recognizing rent expense. The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years.
Rent expense		$ 0.4	$ 0.4

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Expected Future Minimum Payments Under the Non Cancelable Operating Lease (Details) $ in Thousands	Mar. 31, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021 (9 months)	$ 1,057
2022	1,555
2023	1,636
2024	1,685
Thereafter	845
Operating Leases, Future Minimum Payments Due	$ 6,778

Stockholders'_Members' Equity (

Stockholders'/Members' Equity (Deficit) - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Jul. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Beginning balances	$ 209,974,000	$ 195,916,000	$ (57,615,000)	$ 209,974,000		$ (56,011,000)
Payment of initial public offering costs		$ (1,911,000)	0
Common stock, shares issued (in shares)	32,171,560	32,171,560		32,171,560	6,220,050
Stock-based compensation		$ 4,643,000	$ 0
Total number of common shares reserved for issuance	6,122,181	7,778,207		6,122,181
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				15.00%
Common Stock Capital Shares Reserved For Future Issuance	6,122,181	7,778,207		6,122,181
Equity Option
Class Of Stock [Line Items]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		3 years 8 months 12 days
Share-based Payment Arrangement, Plan Modification, Number of Shares		7,747
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value		$ 46.39
Restricted Stock Units and Stock Options
Class Of Stock [Line Items]
Common stock, shares issued (in shares)	2,535,143	2,561,143		2,535,143
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		2 years 8 months 12 days
Share-based Payment Arrangement, Plan Modification, Number of Shares		138,461
2020 Equity Incentive Plan [Member]
Class Of Stock [Line Items]
Total number of common shares reserved for issuance	4,939,678	6,226,540		4,939,678
Shares available for awards, description		On January 1st of each year, commencing with the first January 1st following the effective date of the 2020 Plan, the shares available for awards under the 2020 Plan shall be increased by a number of shares equal to the lesser of 4% of the total number of shares outstanding on the immediately preceding December 31st and such lesser number of shares determined by the Company’s board of directors.
Vesting percentage		25.00%
Vesting period		36 months
Vesting terms, description		Awards under the 2020 Plan generally vest at 25% one year from the vesting commencement date and ratably each month thereafter for a period of 36 months, subject to continuous service.
Common Stock Capital Shares Reserved For Future Issuance	4,939,678	6,226,540		4,939,678
Employees Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Total number of common shares reserved for issuance	464,829	833,993		464,829
Common Stock Capital Shares Reserved For Future Issuance	464,829	833,993		464,829
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum		1.00%
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period		929,658
Class B Units
Class Of Stock [Line Items]
Beginning balances	$ 0	$ 0		$ 0
Common stock, shares issued (in shares)	1,492,059	1,492,059		1,492,059
Vesting period		4 years
IPO [Member]
Class Of Stock [Line Items]
Sale of stock issued in transaction	12,075,000
Sale of stock price per share	$ 18			$ 18
Payment of initial public offering costs	$ 198,300,000
Common stock, shares issued (in shares)	13,876,510			13,876,510
IPO [Member] | Convertible Preferred Stock [Member]
Class Of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	199,791,519			199,791,519
IPO [Member] | Class B Units
Class Of Stock [Line Items]
Common stock, shares issued (in shares)	1,492,059			1,492,059

Stockholders'_Members' Equity_2

Stockholders'/Members' Equity (Deficit) - Summary of Member's deficit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Beginning balance	$ 209,974	$ (56,011)
Net Income Loss	(18,701)	(1,604)
Ending balance	195,916	(57,615)
Common Class A [Member]
Beginning balance		$ 750
Beginning balance, share		54,600,000
Ending balance		$ 750
Ending balance, share		54,600,000
Class C Preferred Units [Member]
Beginning balance		$ 89,345
Beginning balance, share		23,968,178
Ending balance		$ 89,345
Ending balance, share		23,968,178
Common Stock [Member]
Beginning balance	$ 3
Beginning balance, share	32,171,560
Ending balance	$ 3
Ending balance, share	32,171,560
Additional Paid In Capital [Member]
Beginning balance	$ 300,888	$ 2,295
Net Income Loss	0
Ending balance	305,531	2,295
Retained Earnings [Member]
Beginning balance	(90,917)	(148,354)
Net Income Loss	(18,701)	(1,604)
Ending balance	$ (109,618)	149,958
Noncontrolling Interest [Member]
Beginning balance		(47)
Ending balance		$ (47)

Stockholders'_Members' Equity_3

Stockholders'/Members' Equity (Deficit)Stockholders' Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Class Of Stock [Line Items]
Stock-based compensation	$ 4,643,000	$ 0
Research and Development Expense
Class Of Stock [Line Items]
Stock-based compensation	954,000
General and Administrative Expense
Class Of Stock [Line Items]
Stock-based compensation	$ 3,689,000

Stockholders'_Members' Equity_4

Stockholders'/Members' Equity (Deficit) - Summary of Restricted Stock Units (Details) - Restricted Stock Units and Stock Options	Mar. 31, 2021$ / sharesshares
Class Of Stock [Line Items]
Number of Outstanding Shares, Beginning Balance | shares	1,920,037
Number of Outstanding Shares, Ending Balance | shares	1,920,037
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 18
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 18

Stockholders'_Members' Equity_5

Stockholders'/Members' Equity (Deficit) - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, Beginning Balance, Weighted-Average Exercise Price per Share	$ 18
Outstanding, Ending Balance, Weighted-Average Exercise Price per Share | $ / shares		$ 18
Outstanding, Weighted-Average Remaining Contractual Term (years)	9 years 7 months 6 days	9 years 11 months 12 days
Vested and expected to vest, Weighted-Average Remaining Contractual Term (years)	9 years 7 months 6 days
Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, Beginning Balance, Number of Shares	615,106
Granted, Number of Shares	26,000
Stock Options Outstanding, Ending Balance, Number of Shares	641,106	615,106
Vested and expected to vest, Number of Shares	641,106
Granted, Weighted-Average Exercise Price per Share	$ 46.39
Outstanding, Ending Balance, Weighted-Average Exercise Price per Share | $ / shares	19.15
Vested and expected to vest, Weighted-Average Exercise Price per Share	$ 19.15
Outstanding, Aggregate Intrinsic Value at Dec 31,2020	$ 9,848
Outstanding, Aggregate Intrinsic Value at March 31,2021	20,316	$ 9,848
Vested and expected to vest, Aggregate Intrinsic Value	$ 20,316

Stockholders'_Members' Equity_6

Stockholders'/Members' Equity (Deficit) - Summary of Assumptions Used in Black-Scholes Model (Details)	3 Months Ended
	Mar. 31, 2021
Stockholders Equity Note [Abstract]
Expected volatility	76.40%
Risk-free interest rate	52.00%
Expected dividend yield	0.00%
Expected term	4 years 9 months 7 days

Stockholders'_Members' Equity_7

Stockholders'/Members' Equity (Deficit) - Schedule of Common Stock Warrants (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Class Of Stock [Line Items]
Outstanding and Exercisable	717,674
December 17, 2021 [Member]
Class Of Stock [Line Items]
Outstanding and Exercisable	566,586
Exercisable, Weighted-Average Exercise Price per Share | $ / shares	$ 88.25
Expiration Date	Dec. 17, 2021
March 12, 2022 [Member]
Class Of Stock [Line Items]
Outstanding and Exercisable	151,088
Exercisable, Weighted-Average Exercise Price per Share | $ / shares	$ 132.37
Expiration Date	Mar. 12, 2022

Stockholders'_Members' Equity_8

Stockholders'/Members' Equity (Deficit)- Schedule of Common Stock Reserved for Future Issuance (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Jul. 31, 2020
Class Of Stock [Line Items]
Warrants for the purchase of common stock	717,674	717,674
Common stock, shares issued (in shares)	32,171,560	32,171,560	6,220,050
Total number of common shares reserved for issuance	7,778,207	6,122,181
Restricted Stock Units and Stock Options
Class Of Stock [Line Items]
Common stock, shares issued (in shares)	2,561,143	2,535,143
2020 Plan [Member]
Class Of Stock [Line Items]
Total number of common shares reserved for issuance	3,665,397	2,404,535
Employees Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Total number of common shares reserved for issuance	833,993	464,829

Profits Interest Incentive Pl_3

Profits Interest Incentive Plan - Allocation of equity-based Compensation for all class B units (Details) - Class B Units $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ (5,703)
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	(2,523)
General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ (3,180)

Profits Interest Incentive Pl_4

Profits Interest Incentive Plan (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2021
Class B Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Collaboration, License and Op_2

Collaboration, License and Option Agreements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date	2019-12
Upfront Non-Refundable Payment	$ 20,000
Transaction Price Of The Agreement	25,000
Current portion of deferred revenue	$ 19,806		$ 19,806
Amended Bei Gene Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date	2020-10
Reimbursement Of Manufacturing Costs	$ 5,000
Amended Milestone Payments	225,500
Original Milestone Payments	249,000
Performance Obligations Milestone Payment	5,000
Revenues	$ 0	$ 100

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	Mar. 18, 2021	Mar. 31, 2021	Mar. 31, 2020
Related Party Transaction [Line Items]
Interest expense related party		$ 0	$ 59,000
Debt instrument settled date		2020-07
Interest Expense Related Party		$ 0	59,000
Related party transaction, terms and manner of settlement		On March 18, 2021, the Company and Carolyn Anderson Short, its co-founder and Chief of Intellectual Property & Strategy, mutually agreed that Ms. Short would depart the Company on May 31, 2021 following an agreed upon transition period. The Transition Agreement provides for the following severance benefits in exchange for a release of claims by Ms. Short: (i) a lump sum payment equal to eighteen (18) months of Ms. Short’s current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the separation date, and (iii) accelerated full vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units. The modification of these equity awards resulted in an incremental fair value of $7.0 million which will be recognized on a straight-line basis over the transition service period. For the three months ended March 31, 2021, the Company recognized $0.2 million related to the lump sum salary payment and target bonus, and a $1.0 million non-cash charge related to the modified equity awards.
Ms. Short
Related Party Transaction [Line Items]
Number of accelerated full vesting equity awards including stock options	7,747
Number of accelerated full vesting equity awards including restricted stock units	138,461
Incremental Fair Value		$ 7,000,000
Expense related to Lump Sum Salary Payment and Target Bonus		200,000
Non Cash Charge Related To Modified Equity Awards		$ 1,000,000
Biotech Investment Group II LLC
Related Party Transaction [Line Items]
Interest expense related party			20,000
Interest Expense Related Party			20,000
Dr. Jay Short and Carolyn Anderson Short
Related Party Transaction [Line Items]
Interest expense related party			39,000
Debt instrument settled date		2020-07
Interest Expense Related Party			$ 39,000

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Contributions made by Company	$ 0	$ 0